Media Release – SN

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES enters Hong Kong led by newly appointed Managing Director, Martin Law SINGAPORE / HONG KONG, 15 February 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered cancer early detection tests, announced today the set-up of its Hong […]

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES Welcomes Professor Tony Mok to Scientific Advisory Board SINGAPORE, 12 April 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with miRNA-powered cancer early detection tests, announced today the appointment of Professor Tony Mok, a world-renowned medical oncologist, to

NEWSROOM Stay current with MiRXES Newsroom > Media Releases Yayasan MENDAKI and MiRXES announce SG$140,000 MENDAKI – MiRXES scholarship scheme for undergraduate and post-graduate students SINGAPORE, 23 October 2021 – Yayasan MENDAKI (“MENDAKI”) and MiRXES Pte Ltd (“MiRXES”), a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, are

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES appoints Cher Hwa Teo as Senior Vice President, Health Innovation Delivery and Chief of Staff SINGAPORE, 1 October 2021 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, announced today the appointment of Mr.

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES Board of Directors welcomes strategic investor Da Liu from CR-CP Life Science Fund to fast-track groundbreaking early cancer diagnostics Board appointment coincides with an additional US$10 million capital injection into MiRXES from private equity CDG Capital and NHH Ventures SINGAPORE, 21 September 2021 – MiRXES

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES appoints David Capes as its new Global Head of Innovation SINGAPORE, 20 September 2021 – MiRXES Pte Ltd, a biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, announced today the appointment of Dr. David CAPES as Senior Vice President

NEWSROOM Stay current with MiRXES Newsroom > Media Releases MiRXES Secures US$77 Million Series C Funding to Accelerate Multi-Cancer Early Detection Pipeline with Overwhelming Investor Support SINGAPORE, 8 July 2021 – MiRXES Pte Ltd, a biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, announced today it has raised US$77 million